[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645666":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":10,"responsibleParty":29,"collaborators":31,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":10,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":10,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":10},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"conventional-dose TMP-SMX regimen",null,"TMP 15-20 mg\u002Fkg\u002Fday",[13],"Drug: low-dose TMP-SMX regimen",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","low-dose TMP-SMX regimen","TMP \\\u003C15 mg\u002Fkg\u002Fday",[9],[21],{"name":22,"affiliation":5,"role":23},"Yangmin Hu","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","+86 057187783891","zrhym@zju.edu.cn",{"type":30,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[32,34,36],{"name":33,"class":6},"First Affiliated Hospital of Wenzhou Medical University",{"name":35,"class":6},"Zhejiang Provincial Tongde Hospital",{"name":37,"class":38},"First Affiliated Hospital of Ningbo University","NETWORK","100645666","tmp-smx-for-non-hiv-pcp-a-prospective-multicenter-study-100645666",false,"NCT07690410","TMP-SMX for Non-HIV PCP: A Prospective Multicenter Study","Efficacy and Safety of TMP-SMX for Non-HIV-Related PCP: A Prospective Multicenter Observational Study","Inclusion Criteria:\n\n* Age ≥18 years,\n* Meet the diagnostic criteria for Non-HIV-associated PCP,\n* Receiving TMP\u002FSMX as the initial treatment for PCP,\n* Provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women,\n* History of severe allergy or documented intolerance to TMP\u002FSMX,\n* TMP\u002FSMX used for PCP prophylaxis rather than treatment,\n* TMP\u002FSMX treatment duration \\\u003C72 hours at the time of screening,\n* TMP\u002FSMX administered at a supratherapeutic dose (TMP component \\>20 mg\u002Fkg\u002Fday).","ALL","18 Years",{"count":49,"type":50},480,"ESTIMATED","OBSERVATIONAL","Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic infection in immunocompromised patients. Non-HIV-related PCP has a rising incidence, faster progression, and higher mortality than HIV-associated cases. Trimethoprim-sulfamethoxazole (TMP\u002FSMX) is first-line, but standard dosing (TMP 15-20 mg\u002Fkg\u002Fday) is associated with adverse reaction rates of 56%-72%, and prospective evidence is scarce. This prospective, multicentre, observational study aims to compare the efficacy and safety of low-dose (TMP \\\u003C15 mg\u002Fkg\u002Fday) versus conventional-dose TMP\u002FSMX for non-HIV-related PCP, and to explore the value of therapeutic drug monitoring in individualising therapy, without interfering with routine clinical decisions.\n\nThe investigators plan to enrol 480 patients aged ≥18 years with confirmed non-HIV-related PCP receiving TMP\u002FSMX as initial treatment, excluding those with allergy, prophylaxis, treatment \\\u003C72 hours, or supratherapeutic dosing. The primary outcome is treatment failure at day 21 (all-cause death or new invasive ventilation). Secondary outcomes include day-8 oxygenation change, 30- and 90-day mortality, regimen completion, adverse events (CTCAE v6.0), and hospital\u002FICU stay. Propensity score matching will be the main analysis, with inverse probability weighting for sensitivity.",[54],"Pneumocystis Jirovecii Pneumonia in Non-HIV Patients",[56,57,58,59,60],"Trimethoprim-Sulfamethoxazole","Prospective Studies","Multicenter Study","Pneumocystis jirovecii","Pneumonia","NOT_YET_RECRUITING","2026-07-12",{"date":64,"type":65},"2026-07-14","ACTUAL",{"date":67,"type":50},"2026-08-01",{"date":69,"type":50},"2029-06-30",{"name":5,"class":6}]